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Complete hydatidiform mole and partial hydatidiform mole are two abnormal conceptuses that may be identi®ed
by clinical, ultrasonographic, gross morphological, histological, and genetic characteristics. Among all these criteria,
the speci®c diagnosis is generally con®rmed only upon histological review. However, an accurate diagnosis based on
morphological criteria is dif®cult and several studies have shown that misclassi®cations are frequent, even for
experienced pathologists. An erroneous diagnosis may imply that women are either not enrolled in an adequate
b-hCG follow-up with the risk that hydatidiform mole (HM) progresses to choriocarcinoma, or are enrolled in an
unnecessary follow-up. A reliable and complementary method to the pathologic interpretation is a genetic study of
the conceptus to eliminate the diagnostic dilemma by distinguishing non-molar spontaneous abortions from HM and
to de®ne the type of HM. The aim of our study was to review the genetic basis of HM and discuss its relevance in
the routine management of the disorder.
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Introduction
Complete hydatidiform mole (CHM) and partial hydatidiform
mole (PHM) are chromosomally abnormal pregnancies which
may be characterized by clinical, ultrasonographic, gross
morphological, histological and genetic criteria (Vassilakos
et al., 1977; Szulman and Surti, 1978a,b). The distinction
between these two entities is important because CHM has a
greater malignant potential than PHM and, consequently, the
follow-up and the recommendations given to patients may
differ.
Although ultrasonography and b-hCG level may be useful
diagnostic tools in the identi®cation of hydatidiform mole
(HM), the ®nal diagnosis is often con®rmed only upon
histological review. Nevertheless, several studies have shown
that even experienced pathologists may have dif®culties in
distinguishing this disorder and some atypical cases are not
easy to classify de®nitively on the basis of morphologic criteria
alone. For example, it has been found that the concordance rate
between pathologists for the diagnosis of molar pregnancies
(CHM or PHM) ranges from 55±75% (Javey et al., 1979;
Driscoll, 1987; Messerli et al., 1987). PHM may be particularly
dif®cult to identify because it has features in common with
both normal placenta and CHM. Paradinas and co-workers
analysed retrospectively 400 cases of HM initially classi®ed as
PHM. PHM was con®rmed in 50% of cases, CHM in 29%, and
in 21% the diagnosis of HM was excluded (Paradinas, 1998).
These misclassi®cations can be attributed to the absence of
strict morphological criteria to differentiate the HM and
because some characteristics have signi®cant overlap. A useful
complement to the pathological interpretation is to assay the
ploidy of molar tissue with DNA cytometry analysis or
¯uorescence in-situ hybridization (FISH), but it may also be
associated with a signi®cant rate of misclassi®cation, particu-
larly if no fresh tissue is available and if abundant tissue of
maternal origin is present (Bell et al., 1999). Moreover, ploidy
analysis cannot be used to distinguish a diploid mole from
spontaneous abortion which can also exhibit hydropic changes
and trophoblast hyperplasia mimicking HM.
Genetic analysis may eliminate this dilemma and the aim of
this study is to review the genetic basis of HM and to discuss its
relevance in the routine management of the disorder.
Complete hydatidiform mole (CHM)
Histopathology
CHM is characterized by a diffuse trophoblastic hyperplasia
with hydrops involving almost all the villi and resembling
bunches of grapes, usually with an absence of a fetus or fetal
tissue such as blood vessels or amniotic membranes, and
isoften associated with cytologic atypia (Figures 1A,B). It was
previously believed that CHM never contained fetal tissue but
several reports have shown that this is incorrect and some fetal
tissues may exist. This observation is not surprising since it has
been demonstrated that the stromal tissue of the chorionic villi,
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also present in CHM, originates from the embryonic meso-
derm. It is presumed that in CHM the embryo dies very early in
pregnancy. Recent improvements in the quality of sonography
have resulted in the earlier detection of abnormal pregnancy
and the evacuation of molar tissue in the ®rst trimester of
pregnancy, thus increasing the chances of detecting embryonic
development. Several reports have demonstrated cases of
androgenetic CHM with embryonic tissue not belonging to a
twin pregnancy (Fisher et al., 1997; Paradinas et al., 1997). In
early gestation (6±10 weeks gestation), hydropic villi may not
Figure 1. Hydatiform mole. (A) Complete hydatidiform mole with trophoblastic hyperplasia (arrow) 100x. (B) Complete hydatidiform mole
with cellular atypia (same area as Figure 1A) and mitoses (arrow). 400x. (C) Partial hydatidiform mole with focal hyperplasia (arrow) 100x.
(D) Partial hydatidiform mole (PHM) with focal trophoblastic hyperplasia and nuclear atypia (arrow) 4003 (same area as Figure 1C). These
characteristics have signi®cant overlap with a complete hydatidiform mole and in this case, the diagnosis of PHM was con®rmed by genetic
analysis.
Figure 5. This shows an example of 46,XX complete hydatidiform mole. Two X-chromosomes speci®c signals after FISH on placental tissue
are seen. Same specimen as Figure 3.
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be apparent and molar stroma may be vascular; subsequently,
these early CHMs may be misdiagnosed as PHMs (Paradinas
et al., 1997).
Origin and genetic constitution of CHM
Genetic studies have demonstrated that CHM are mostly
androgenetic and diploid with a 46,XX or 46,XY karyotype.
Moles with a 46,YY karyotype have never been described,
probably because such pregnancies are not viable. CHM arises
from the fertilization of an empty oocyte (the female genome is
completely extruded or inactivated) by one or two sperm (Kajii
and Ohama, 1977; Szulman and Surti, 1978a,b; Ohama et al.,
1981). Two mechanisms may explain the genesis of CHM
(Figure 2). Theoretically, a third mechanism may involve
fertilization through a diploid sperm due to nondivision at
meiotic division, but evidence is lacking (Petignat, 2000).
Although the chromosomes of CHM are mostly entirely of
paternal origin, mitochondrial DNA is of maternal origin
(Azuma et al., 1991).
CHM and malignancy
Following uterine evacuation, ~20% of patients with a CHM
develop a persistent trophoblastic tumour (PTT); of these, ~4%
will develop a metastatic tumour (Osathanondh et al., 1975;
Berkowitz and Goldstein, 1996). Follow-up of these patients
includes a weekly determination of b-hCG measurements until
undetectable levels for three consecutive weeks, followed by
monthly evaluations for 12 consecutive undetectable levels.
However, if the patient's b-hCG values reach the normal range
within two months after evacuation, follow-up may be limited
to six months. Upon completion of follow-up, the patient may
choose to conceive at any time (current policy in our
institution).
Contribution of genetic studies and perspectives
CHM may be either monospermic if it arises from the doubling
of a haploid sperm (homozygous moles), or dispermic if it
arises from two haploid sperm (heterozygous moles) (Figure 3)
(Ohama et al., 1981). Homozygous and heterozygous CHM are
two genetically distinct entities which can only be distin-
guished on the basis of genetic analysis. Studies have suggested
that heterozygous mole may have a more malignant potential
than its homozygous counterpart. Wake et al. found that three
of ®ve patients with heterozygous moles had required
treatment for post-molar trophoblastic tumour, compared
with only one out of 21 patients with homozygous moles
(Wake et al., 1984). However, these results have not been
con®rmed by other investigators who found no signi®cant
different risk between both groups (Lawler et al., 1982a; Kajii
et al., 1984; Lawler and Fisher 1987; Lawler et al., 1991;
Mutter et al., 1993). However, it should be mentioned that the
number of published cases is small and additional studies are
required to determine conclusively whether the heterozygous
form is potentially more aggressive. If one form has really a
higher malignant potential, it will be important to distinguish
between both forms so that the relative risk can be assessed.
Figure 2. Mechanisms of formation of diploid moles.
Figure 3. PCR ampli®ed products of 3 microsatellite markers from
chromosomes 2,9 and 16 on DNA from maternal, paternal
peripheral blood and curettage specimen separated by gel
electophoresis (denaturing PAGE). The unique allele observed for
marker D16S3046 shows pattern of a single paternal allelic
contribution (allele 2; arrow). For markers D2S123 and D9S1118,
the unique paternal contribution is shown by the main strong allele
(arrow; D2S123-allele2, D9S1118-allele 1). For these 2 markers,
additional alleles (stars) of weak intensity can be explained by a
minor contamination from maternal cells which is not revealed in
marker D16S3046.
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Partial hydatidiform mole (PHM)
Histopathology
PHM is generally accompanied by a fetus, or shows evidence
of a previous existence of a fetus by the presence of
erythroblasts or fetal membranes. Trophoblast hyperplasia is
very focal and circumferential excess trophoblast often
invaginates into the stroma to form characteristic scalloped
outlines and round pseudoinclusions (Figure 1C); nuclear
trophoblastic atypia may be present (Figure 1D). PHM must be
extensively sampled as focal hyperplasia of trophoblast may
not be detected and, subsequently, misdiagnosed as a banal
hydropic abortus. On the other hand, non-molar pregnancies in
certain speci®c conditions, such as chromosomal abnormalities
may have irregular villi and round inclusions like a PHM and
may be misclassi®ed as partial mole (Chew et al., 2000). The
hydropic abortus is completely benign, whereas a signi®cant
risk of PTT exists for those patients with a PHM.
Origin and genetic constitution of PHM
Partial moles are generally triploid gestations in which the
extra chromosomal load is of paternal or maternal origin; the
karyotype is 69,XXY, 69,XXX, or rarely 69,XYY (Jacobs
et al., 1982; McFadden and Kalousek, 1991; McFadden et al.,
1993). Triploid PHM may either arise through fertilization of a
haploid oocyte by one spermatozoon which doubles its
chromosomes after fertilization, or two sperm (one maternal
and two paternal contributions), or through the fertilization of a
diploid oocyte by one spermatozoon (two maternal and one
paternal contribution) (Figure 4) (Lawler et al., 1982b; Jacobs
et al., 1982). A diploid oocyte originates from failure of
meiosis I or II. Another mechanism at the origin of diploid
oocyte involves the fusion of two ova (`dieggy') (Zaragoza
et al., 2000)
PHM and malignancy
PHM has a lower malignancy potential than CHM, with an
incidence of PTT ranging from 4±11% and rarely transforms
into choriocarcinoma (Palmer, 1994; Seckl et al., 2000).
However, even if the risk of PTT is low, the current
management of all patients with PHM is routinely to monitor
b-hCG levels after evacuation. Follow-up includes a weekly
b-hCG determination until undetectable levels are recorded for
three consecutive weeks. The b-hCG level is then recorded
monthly until normal for six consecutive months and patients
are recommended to use contraception during that period
(current policy in our institution).
Figure 4. Mechanisms of formation of triploidy.
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Contribution of genetic studies and perspectives
Studies of the genetic origins of triploid PHM have demon-
strated that fetal and placental phenotypes of triploid pregnan-
cies correlate with parental origin and permit the de®nition of
two types (Jacobs et al. 1982; McFadden and Kalousek 1991;
McFadden et al. 1993; Zaragoza et al., 2000).
Type I triploid fetus or paternally-derived or diandric
triploidy
The fetus is of normal size for gestational age and the placenta
is abnormally large and cystic (Figure 4). In most cases, the
fetus dies a few weeks after conception and, to our knowledge,
no fetus of paternal origin has survived until term.
Type II triploid fetus or maternally-derived or digynic
triploidy
The fetus is growth-retarded and the placenta is abnormally
small without cystic formation (Figure 4). Some cases of
triploid fetuses of maternal origin have been previously
described as born alive with a survival of a few months
(Fryns et al., 1977).
Currently, it is unclear if type I (diandric) and type II
(digynic) triploidies have different malignant potential and if
the distinction will have a direct impact on the management
and counselling of patients. However, it appears that PHM type
I is more aggressive than type II. Seckl et al. (2000) studied
3000 patients with PHM, three of whom developed a
choriocarcinoma; genetic analysis showed that all three were
PHM type I.
Unusual cases
Twin pregnancy consisting of an HM and a normal fetus
The occurrence of such a pregnancy is infrequent with an
incidence estimated in the range of 1/10 000 to 1/100 000
pregnancies, but it is assumed that this diagnosis is grossly
underrated. Firstly, because fetal loss may occur in early
pregnancy without leaving gross evidence of `a vanishing twin'
and, secondly, because the differential diagnosis between HM
co-existent with a fetus and partial mole is dif®cult and such
situations are commonly mistaken for PHM (Petignat et al.,
2001). First reports with small series indicated that the
distinction is important given that the risk of PTT is much
higher (~50% of cases) in a twin pregnancy combining a CHM
and a normal fetus than in singleton CHM (Steller et al., 1994;
Fishman et al., 1998; Petignat et al., 2002). However, a recent,
larger study did not con®rm these results and found that
patients with a twin pregnancy involving an HM showed no
increased risk of PTT over singleton CHM (Sebire et al., 2002).
CHM with biparental contribution
Several investigators have reported cases of CHM with genetic
markers consistent with a normal conception. The constitution
has both a paternal and maternal contribution to the genome,
but are pathologically identical as classical androgenetic CHM
(Jacobs et al., 1980; Davis et al., 1984; Kovacs et al., 1991;
Fisher et al., 1997; Moglabey et al., 1999; Fisher et al., 2000).
Such cases suggest that there may be more than two subgroups
of CHM and other mechanisms could be involved that cause
molar placental changes. Recently Fisher and colleagues have
studied an HM of biparental origin (by comparing micro-
satellites polymorphism) and found no evidence of chromo-
somal uniparental disomy, suggesting that HM in these cases
may results from uniparental disomy of only a small region of
the paternal genome (Fisher et al., 2000). Cases with biparental
origin could be a valuable tool in identifying the imprinted
gene involved in molar development.
HM with unusual ploidy
Although the majority of PHM are triploid, uncommon DNA
content such as haploid, diploid, tetraploid and mosaicism
PHM have been reported (Vejerslev et al., 1987; Lage et al.,
1992). Cases of triploid, tetraploid and mosaicism CHM have
been reported also. These unusual ploidies associated with both
partial and CHM render their differentiation and classi®cation
exceptionally dif®cult. However, the most important factor
appears to be the ratio of paternal and maternal chromosomes
and not the ploidy of the tissue (Vejerslev et al., 1987). For
example, tetraploidy without maternal genome has the
pathologic features of CHM and if maternal genome is present,
the histopathology resembles a PHM. The implications of this
rare condition in terms of malignancy are still unknown, but it
seems that the degree of molar change correlates with both the
proportion of paternal contribution and the risk of PTT.
Discussion
As mentioned previously, the diagnosis of HM is dif®cult and
the histological criteria may be insuf®cient to distinguish CHM
from PHM and HM from a non-molar abortion exhibiting
hydropic change and trophoblast hyperplasia. Pathologists may
be in doubt of the histological diagnosis (particularly patholo-
gists inexperienced in the diagnosis of molar pregnancies)
because, in many cases, products of conceptions show some
histological evidence of hydropic change and the pathologist
has to make a decision as to whether it is a molar or a non-
molar pregnancy. Clinicians require an accurate diagnosis of
these entities for both prognosis and patient management and a
diagnosis re¯ecting uncertainty such as `cannot rule out molar
pregnancy' or `lesion suspicious for HM' is insuf®cient. These
dif®culties have probably increased over recent years with the
advent of more sophisticated prenatal screening tests and the
use of high frequency probes for transvaginal sonogram which
allow an earlier detection of abnormal pregnancy and earlier
evacuation.
Alternative approaches have been developed to provide
more objective diagnostic criteria to distinguish different forms
of trophoblastic disease. An adjunct to histological diagnosis
may be to determine the cell ploidy by means of ¯ow
cytometry or ¯uorescent in-situ hybridization (FISH). The
combination of morphology and DNA content may be a useful
aid in the differential diagnosis of molar pregnancy and
improve the pathologists' concordance (Conran et al., 1993).
However, cytometry or FISH results will not aid distinction of
CHM from non-molar gestation given that there is a signi®cant
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overlap in the histologic and ploidy characteristics between
these two entities (Bell et al., 1999). Recently, an immuno-
histopathological staining technique using p57kip2 expression
analysis has been reported as a good diagnostic adjunct
complementary to histology and ploidy analysis to distinguish
CHM from other types of conceptuses. This method could be
easier to perform and interpret than genetic analysis in a
pathology setting; however additional studies are required to
determine the speci®city and sensitivity of the technique
(Zaragoza et al. 2000).
In the past, the laborious cytogenetic preparation of cell
cultures and the potential misinterpretation on analysis of size
and staining variants have precluded routine genetic studies.
Currently, new molecular biology tools have made feasible the
analysis of both molar and parental DNA on a routine basis.
Such examinations may be performed, for example, by PCR
ampli®cation of several microsatellites markers of DNA and by
comparing the sequences in the molar tissue and in genitors. In
Figure 3, the analysis of the alleles (electrophoretic band) of
each DNA indicates that the genetic content of the mole is of
monospermic origin. This analysis is however semi-quantita-
tive and does not inform about the ploidy of the molar tissue.
This information can be determined by (FISH) using chromo-
some-speci®c DNA probes (Figure 5). Both methods are rapid
and less costly than cell culture, can be assessed on either fresh
tissues or paraf®n-embedded specimens, thus providing accur-
ate information on the genetic constitution of the conceptus. By
combining histopathology, FISH and DNA analysis of the
microsatellites, it is possible to distinguish CHM from PHM, or
banal hydropic abortion from an HM.
We consider that the management of HM requires an
accurate diagnosis that should be based on a histopathology
and conclusively supported by a genetic analysis. Ideally, a
routine genetic examination should be done as an adjunct to
pathological examination each time that a trophoblastic disease
is suspected. Some will argue that there is no founding for this
routine analysis but although this diagnostic pathway is
certainly more costly, we consider that the efforts justify the
bene®t for the patient's management. Ultimately, it should
prevent the development of choriocarcinoma, because although
most of these patients can be successfully treated with current
chemotherapy, there are still those who will die from this
disease or receive inadequate treatment, usually because of a
delayed or erroneous diagnosis (Seckl et al., 2000). The
reliability of the diagnosis is crucial for appropriate counselling
and to determine if a patient falls into a `short-term' or `long-
term' follow-up to minimize the period during which patients
are recommended to use contraceptive methods. In some
instances, for example in women having a `lesion suspicious
for HM', the diagnosis could be con®rmed or ruled out, thus
avoiding an unnecessary follow-up. This may be of particular
importance in `older patients' having dif®culties in conceiving
and for whom a one-year wait may be extremely distressing.
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